[A new chondroprotector--polyvinylpyrrolidone for treating osteoarthrosis patients].
The authors demonstrate the role of chondroprotector therapy in the management of patients with osteoarthrosis (OA). They suggest the use of the polymeric drug polyvinylpyrrolidone as artificial synovial fluid. The drug is administered intra-articularly and is capable of replacing pathological synovial fluid. It has been established that 10 and 20% polyvinylpyrrolidone solutions possess high viscosity and low compressibility, they are isolated from the articular cavity for 6 to 7 days and manifest antiarthrosis action in chondrocytic cultures. The short- and long-terms results of the clinical trials of polyvinylpyrrolidone solutions allow recommending them for the treatment of OA.
A A
AA
Matulis
I G
IG
Dadonene
R I
RI
Grigene
D000818:Animals; D002356:Cartilage / Q000166:cytology / Q000187:drug effects*; D002478:Cells, Cultured / Q000187:drug effects; D004341:Drug Evaluation; D004353:Drug Evaluation, Preclinical; D005347:Fibroblasts / Q000187:drug effects; D006801:Humans; D007270:Injections, Intra-Articular; D007368:Interferometry; D007834:Lasers; D010003:Osteoarthritis / Q000188:drug therapy*; D011205:Povidone / Q000493:pharmacokinetics / Q000494:pharmacology / Q000627:therapeutic use*; D011817:Rabbits; D012996:Solutions; D013582:Synovial Fluid / Q000187:drug effects; D014783:Viscosity
D012996:Solutions; D011205:Povidone
Novyĭ khondroprotektor--polivinilpirrolidon dlia lecheniia bol'nykh osteoartrozom.